Trial Profile

Clinical Study of CTX 114

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CTX 114 (Primary)
Indications Dry macular degeneration; Wet age-related macular degeneration
Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
Sponsors Character Biosciences

Most Recent Events

01 Apr 2025 New trial record
25 Mar 2025 According to Character Biosciences media release, company announced today an oversubscribed $93 million Series B financing round to accelerate the advancement of its pipeline of precision therapies to treat degenerative eye diseases.The Series B funding will support Phase 1 and Phase 2 proof-of-concept studies for CTX203 and CTX114.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com